Del Labs Q1
This article was originally published in The Rose Sheet
Executive Summary
Sally Hansen and N.Y.C. New York Color brands drive 19.8% first quarter sales gain, Uniondale, N.Y. company says April 24. Net sales for the three months reached $79.9 mil. Net earnings increased 289.6% to $4.9 mil., including an after-tax gain of $1.5 mil. from sale of vacant land in 2002, the company adds. Del Labs also markets Naturistics cosmetics and Orajel...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.